Page 32 - NZBRI_Annual Report 2017_FA

30 New Zealand Brain Research Institute

NZBRI 2017 Statement of Service Performance

Output
Canterbury people will receive improved care or levels of assessment by

involvement in pharmaceutical trials or international observational studies

Performance Measures Performance

Quantity Number of Canterbury DHB 3044 outpatient visits
outpatient visits hosted (13% increase from 2016) conducted
onsite by CDHB neurologists,
attending to 2260 patients.)

Number of STAR 1 trial — Double-blind study of cannabidiol for partial onset
patients epilepsy. Study continued in 2017. 9 patients were assessed over 31 visits.

active STAR 2 trial — Open-label study of cannabidiol transdermal gel for
involved in partial onset epilepsy. Study commenced in 2017. 5 patients assessed
studies
over 62 visits.
Duodopa study — Open-label study of levodopa/carbidopa

intestinal gel for Parkinson’s patients: one patient, 3 visits.
Study ended in September 2017
STEADFAST study — Double-blind study of azeliragon for
mild Alzheimer’s. Study continued in 2017, with 7 patients assessed

over 21 visits.

ENROLL HD — Observational study of families with Huntington’s.
Ongoing longitudinal study, with 100th patient recruited in 2017.
As some previously recruited patients have died or did not attend
follow-up, 80 patients were assessed over 80 sessions.

Daybreak study — Five-year trial of ozanimod in people with relapsing
multiple sclerosis. Recruitment closed. Two participants.

Endorse study — Twelve-year trial of tecfidera in people with relapsing
multiple sclerosis. Recruitment closed. Two participants remaining.

ESTEEM study — Observational study of people with relapsing multiple
sclerosis taking tecfidera for the first time. Four participants recruited.